Trial · NCT03821623
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
NCT03821623, Phase 2, Active not recruiting, Douglas Seals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults. Trials, record NCT03821623. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03821623
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT number
- NCT03821623
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 118 participants, estimated
- Lead sponsor
- Douglas Seals
- Conditions
- Hypertension, Aging
- Interventions
- Nicotinamide riboside, Placebo
- First posted
- 2019-01-30
- Last updated
- 2026-10-02
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Systolic blood pressure | 3 months | Resting systolic blood pressure |
| Secondary | Ambulatory blood pressure | 3 months | 24-hour mean blood pressure |
| Secondary | Arterial stiffness | 3 months | Carotid-femoral pulse wave velocity |
| Other | Number and severity of adverse events (safety) | 3 months | Monitoring and documentation of number and type of adverse events |
| Other | Number of participants that dropout due to adverse events (tolerability) | 3 months | Monitoring subject dropout due to adverse events |
| Other | Adherence to the intervention (percentage of prescribed pills consumed) | 3 months | Counting returned pills on a bi-weekly basis to determine what percentage of prescribed pills subjects take. |
| Other | NAD+ and related metabolite blood levels | 3 months | Blood samples will be analysed using high performance liquid chromatography-mass spectronomy analysis for levels of NAD+ and related metabolites including: NADP+, nicotinic acid adeniene dinucleotide, nicotinamide, and nicotinamide mononucleotide. |
| Other | Sympathetic activity | 3 months | Plasma norepinephrine, a marker of sympathetic activity, will be measured by high performance liquid chromatography |
| Other | Oxidative stress | 3 months | Plasma oxidized LDL, a marker of oxidative stress, will be measured by ELISA |
| Other | Inflammation | 3 months | Plasma interleukin-6, a marker of inflammation, will be measured by ELISA |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03821623
GET https://conductscience.org/api/trials/v1/NCT03821623/registered